Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001437749-17-017263
Filing Date
2017-10-18
Accepted
2017-10-18 17:34:15
Documents
2
Period of Report
2017-10-16

Document Format Files

Seq Description Document Type Size
1 FORM 4 rdgdoc.html 4  
1 FORM 4 rdgdoc.xml 4 3496
2 corvesepoa.htm EX-24 5600
  Complete submission text file 0001437749-17-017263.txt   10754
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Issuer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 7389 Services-Business Services, NEC

Mailing Address C/O ANTIGENICS INC. 162 FIFTH AVENUE, SUITE 900 NEW YORK NY 10010
Business Address
Corvese Brian (Reporting) CIK: 0001393207 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-51353 | Film No.: 171143262